Palatin to Host Virtual KOL Event Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance on May 8, 2024

/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

Related Keywords

United States ,Kansas ,Kansas City ,American ,Jesse Richards ,Prnewswire Palatin Technologies Inc ,Palatin Technologies Inc ,University Of Oklahoma ,Exchange Commission ,Securities Exchange ,University Kansas School Of Medicine ,Oklahoma State University College ,Osteopathic Medicine ,University Kansas School ,Melanocortin Receptor ,Palatin Technologies ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Nc ,